Complete Metabolic Response to Combined Immune Checkpoint Inhibition after Progression of Metastatic Colorectal Cancer on Pembrolizumab: A Case Report

Krekeler, C; Wethmar, K; Mikesch, JH; Kerkhoff, A; Menck, K; Lenz, G; Schildhaus, HU; Wessolly, M; Hoffmann, MW; Pascher, A; Asmus, I; Wardelmann, E; Bleckmann, A (2023)

In: International Journal of Molecular Sciences, 24(15), 12056.

Research article (journal)

Radiomics of Tumor Heterogeneity in 18F-FDG-PET-CT for Predicting Response to Immune Checkpoint Inhibition in Therapy-Naïve Patients with Advanced Non-Small-Cell Lung Cancer.

Ventura D; Schindler P; Masthoff M; Görlich D; Dittmann M; Heindel W; Schäfers M; Lenz G; Wardelmann E; Mohr M; Kies P; Bleckmann A; Roll W; Evers G (2023)

In: Cancers, 15(8), 2297.

Research article (journal)

First-In-Class CD13-Targeted Tissue Factor tTF-NGR in Patients with Recurrent or Refractory Malignant Tumors: Results of a Phase I Dose-Escalation Study

Schliemann C, Gerwing M, Heinzow H, Harrach S, Schwöppe C, Wildgruber M, Hansmeier AA, Angenendt L, Berdel AF, Stalmann U, Berning B, Kratz-Albers K, Middelberg-Bisping K, Wiebe S, Albring J, Wilms C, Hartmann W, Wardelmann E, Krähling T, Heindel W, Gerss J, Bormann E, Schmidt H, Lenz G, Kessler T, Mesters RM, Berdel WE (2020)

In: Cancers, 12(6).

Research article (journal)

Requirement for YAP1 signaling in myxoid liposarcoma

Trautmann M, Cheng Y, Jensen P, Azoitei N, Brunner I, Hüllein J, Slabicki M, Isfort I, Cyra M, Berthold R, Wardelmann E, Huss S, Altvater B, Rossig C, Hafner S, Simmet T, Ståhlberg A, Åman P, Zenz T, Lange U, Kindler T, Scholl C, Hartmann W, Fröhling S (2019)

In: EMBO Molecular Medicine, 2019.

Research article (journal)

Phosphatidylinositol-3-kinase (PI3K)/Akt signaling is functionally essential in myxoid liposarcoma

Trautmann M, Cyra M, Isfort I, Jeiler B, Krüger A, Grünewald I, Steinestel K, Altvater B, Rossig C, Hafner S (2019)

In: Molecular Cancer Therapeutics, 2019.

Research article (journal)

Publications

Operated by

Top-Links

PD-L1 on large extracellular vesicles is a predictive biomarker for therapy response in tissue PD-L1-low and -negative patients with non-small cell lung cancer Schöne, Nadja; Kemper, Marcel; Menck, Kerstin; Evers, Georg; Krekeler, Carolin; Schulze, Arik Bernard; Lenz, Georg; Wardelmann, Eva; Binder, Claudia; Bleckmann, Annalen (2024) In: Journal of extracellular vesicles, 13(3), e12418. Research article (journal)
Complete Metabolic Response to Combined Immune Checkpoint Inhibition after Progression of Metastatic Colorectal Cancer on Pembrolizumab: A Case Report Krekeler, C; Wethmar, K; Mikesch, JH; Kerkhoff, A; Menck, K; Lenz, G; Schildhaus, HU; Wessolly, M; Hoffmann, MW; Pascher, A; Asmus, I; Wardelmann, E; Bleckmann, A (2023) In: International Journal of Molecular Sciences, 24(15), 12056. Research article (journal)
Efficacy of Multimodality Approach in Patients With Recurrent Head and Neck Squamous Cell Carcinoma. Hoell, PA; Elsayad, K; Berssenbruegge, H; Hering, D; Kittel, C; Kleinheinz, J; Bleckmann, A; Evers, G; Wardelmann, E; Rudack, C; Eich, HT (2023) In: Anticancer Research, 43(3). Research article (journal)
Radiomics of Tumor Heterogeneity in 18F-FDG-PET-CT for Predicting Response to Immune Checkpoint Inhibition in Therapy-Naïve Patients with Advanced Non-Small-Cell Lung Cancer. Ventura D; Schindler P; Masthoff M; Görlich D; Dittmann M; Heindel W; Schäfers M; Lenz G; Wardelmann E; Mohr M; Kies P; Bleckmann A; Roll W; Evers G (2023) In: Cancers, 15(8), 2297. Research article (journal)
563P First-in-class CD13-targeted tissue factor tTF-NGR in patients with recurrent or refractory malignant tumours: Safety and pharmacokinetic results of a phase I study Schliemann C, Gerwing M, Heinzow H, Harrach S, Schwöppe C, Wildgruber M, Hansmeier AA, Angenendt L, Berdel AF, Kessler T, Wilms C, Hartmann W, Wardelmann E, Krähling T, Heindel W, Gerss J, Schmidt H, Lenz G. Mesters R, Berdel WE (2020) In: (eds.), . (kein Verlag angegeben). Research article in edited proceedings (conference)
First-In-Class CD13-Targeted Tissue Factor tTF-NGR in Patients with Recurrent or Refractory Malignant Tumors: Results of a Phase I Dose-Escalation Study Schliemann C, Gerwing M, Heinzow H, Harrach S, Schwöppe C, Wildgruber M, Hansmeier AA, Angenendt L, Berdel AF, Stalmann U, Berning B, Kratz-Albers K, Middelberg-Bisping K, Wiebe S, Albring J, Wilms C, Hartmann W, Wardelmann E, Krähling T, Heindel W, Gerss J, Bormann E, Schmidt H, Lenz G, Kessler T, Mesters RM, Berdel WE (2020) In: Cancers, 12(6). Research article (journal)
κB-Ras and Ral GTPases regulate acinar to ductal metaplasia during pancreatic adenocarcinoma development and pancreatitis Beel, Stephanie; Kolloch, Lina; Apken, Lisa; Jürgens, Lara, Bolle, Andrea; Sudhof, Nadine, Ghosh, Sankar; Wardelmann, Eva; Meisterernst, Michael; Steinestel, Konrad; Oeckinghaus, Andrea (2020) In: Nature Communications, 11: 3409. Research article (journal)
Requirement for YAP1 signaling in myxoid liposarcoma Trautmann M, Cheng Y, Jensen P, Azoitei N, Brunner I, Hüllein J, Slabicki M, Isfort I, Cyra M, Berthold R, Wardelmann E, Huss S, Altvater B, Rossig C, Hafner S, Simmet T, Ståhlberg A, Åman P, Zenz T, Lange U, Kindler T, Scholl C, Hartmann W, Fröhling S (2019) In: EMBO Molecular Medicine, 2019. Research article (journal)
SS18-SSX-dependent YAP/TAZ Signaling in Synovial Sarcoma Isfort I, Cyra M, Elges S, Kailayangiri S, Altvater B, Rossig C, Steinestel K, Grünewald I, Huss S, Eßeling E (2019) In: Clinical Cancer Research, 2019. Research article (journal)
Phosphatidylinositol-3-kinase (PI3K)/Akt signaling is functionally essential in myxoid liposarcoma Trautmann M, Cyra M, Isfort I, Jeiler B, Krüger A, Grünewald I, Steinestel K, Altvater B, Rossig C, Hafner S (2019) In: Molecular Cancer Therapeutics, 2019. Research article (journal)